Novo Nordisk A/S $NVO Shares Bought by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 38.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,491 shares of the company’s stock after purchasing an additional 19,469 shares during the period. Pinnacle Associates Ltd.’s holdings in Novo Nordisk A/S were worth $3,587,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Berkeley Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 42.5% in the 4th quarter. Berkeley Capital Partners LLC now owns 5,505 shares of the company’s stock worth $280,000 after purchasing an additional 1,641 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Novo Nordisk A/S by 196.1% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,066 shares of the company’s stock worth $207,000 after purchasing an additional 2,693 shares during the last quarter. Allworth Financial LP increased its position in shares of Novo Nordisk A/S by 258.9% in the fourth quarter. Allworth Financial LP now owns 131,741 shares of the company’s stock worth $6,703,000 after acquiring an additional 95,033 shares in the last quarter. Independent Advisor Alliance increased its position in shares of Novo Nordisk A/S by 2.2% in the fourth quarter. Independent Advisor Alliance now owns 38,789 shares of the company’s stock worth $1,974,000 after acquiring an additional 844 shares in the last quarter. Finally, Argos Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth approximately $304,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO stock opened at $44.71 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The stock has a market cap of $199.63 billion, a P/E ratio of 10.50, a P/E/G ratio of 4.08 and a beta of 0.77. The firm has a 50 day simple moving average of $39.73 and a 200 day simple moving average of $46.69. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Research analysts anticipate that Novo Nordisk A/S will post 3.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on NVO shares. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research report on Tuesday, March 3rd. Finally, TD Cowen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.